Multicentricity in different molecular subtypes of breast cancer: A cross-sectional study in Isfahan

• Published in: Advanced biomedical research 2023-01, Vol.12 (1), p.9-9
• Main Authors: Baradaran, Azar, Derakhshan, Maryam, Raeisi, Saba, Neshat, Sina, Raeisi, Sina
• Format: Article
• Language: English
• Subjects: Breast cancer; breast neoplasms; Cancer; Cross-sectional studies; ErbB-2 protein; Estrogen receptors; Estrogens; Frequency distribution; Growth factors; immunohistochemistry; mastectomy; Medical records; Menstruation; multicentricity; Oncology, Experimental; Original; Progesterone; Prognosis; Receptors
• ISSN: 2277-9175; 2277-9175
• DOI: 10.4103/abr.abr_208_21

Background: Breast cancer is the most common cancer leading to death in women. Women with multicentric breast cancer were reported more likely to have poor prognosis. Here, we decided to study and compare the frequency distribution of multicentricity in different subtypes of breast cancer. Materials and Methods: This is a cross-sectional study that was performed in 2019-20 on medical records and breast pathology reports of 250 patients who undergone mastectomy due to breast cancer. Demographic data of all patients including age, along with other medical data such as menstruation condition, breast cancer grade, multicentricity status, stage, and expression of estrogen receptor (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) receptors were collected from medical records. Samples were divided into four subtypes of Luminal B, Luminal A, HER2 expressing, and basal-like. Results: The mean age of patients was 50.21 ± 11.15 years. Ninety-five patients (38%) had multicentricity and HER2 expressing (48.5%) and Luminal A (41.4%) were most common in patients with multicentricity. In addition, basal-like group presented with least multicentricity (13.5%) among the subtypes (P = 0.008). We also showed significant increased chances of multicentricity in Luminal B (odds ratio [OR] = 3.782) (P = 0.033), Luminal A (OR = 5.164) (P = 0.002), and HER2-expressing group (OR = 5.393) (P = 0.011). Conclusions: Taken together, we showed significantly increased chances of multicentricity in patients with HER2-expression, Luminal A, and Luminal B groups compared to basal-like group or triple negative. These results were in line with most previous studies; however, we showed higher rates of multicentricity among our population compared to some previous reports.